Biomarkers, or otherwise referred to as biological markers (e.g. genes, molecules, unique chemicals, proteins, brain function, etc), are indicators of a disease that can be measured with scans, blood tests or clinical assessments. At Dementech Neurosciences we are implementing this approach with state-of-the-art procedures following years of research & development including projects with Universities such as King’s College London.
Transferring promising specific, sensitive and accurate biomarkers of chronic disorders such as Parkinson’s disease (PD) and Alzheimer’s disease (AD) into clinical practice has been one of the major goals at Dementech Neurosciences. We believe that this will significantly benefit their management and planning an efficient approach to treatment.
Patients or people at risk enrolled into Dementech’s Clinical Practice will have access to the latest developments in PD and AD biomarkers tools. This includes the state-of-the-art of genetic profiling; molecular brain imaging of dopamine and serotonin system, brain metabolism, beta-amyloid and tau load with PET/CT; diagnostic imaging with advanced structural and functional MRI; blood tests following latest techniques and discoveries; and assessments of symptoms including detection of subtle changes in movement, behaviour and memory using our unique clinical services and cutting-edge Neuropsychology Lab.
Assessments using Dementech Biomarker Tools are unique and will help the early diagnosis and prognosis of Parkinson’s disease and Alzheimer’s disease and for monitoring the progression of motor and memory symptoms and the response to treatment. Patients or people at risk will also have access to an innovative combination of biomarkers termed PRECODE-1 and PRECODE-2 with or without the addition of genetic profiling. Consultants with special expertise in Movement Disorders and Dementia will determine the level of impairment and will guide you through implementation of individualised management strategies and techniques.